Electronegative Low-Density Lipoprotein is Associated with Dense Low-Density Lipoprotein in Subjects with Different Levels of Cardiovascular Risk

Abstract

Dyslipidemias and physicochemical changes in low-density lipoprotein (LDL) are very important factors for the development of coronary artery disease (CAD). However, pathophysiological properties of electronegative low-density lipoprotein [LDL(−)] remain a controversial issue. Our objective was to investigate LDL(−) content in LDL and its subfractions (phenotypes A and B) of subjects with different cardiovascular risk. Seventy-three subjects were randomized into three groups: normolipidemic (N; n = 30) and hypercholesterolemic (HC; n = 33) subjects and patients with CAD (n = 10). After fasting, blood samples were collected and total, dense and light LDL were isolated. LDL(−) content in total LDL and its subfractions was determined by ELISA. LDL(−) content in total LDL was lower in the N group as compared to the HC (P < 0.001) and CAD (P = 0.006) groups. In the total sample and in those of the N, HC, and CAD groups, LDL(−) content in dense LDL was higher than in light LDL (P = 0.001, 0.001, 0.001, and 0.033, respectively) The impact of LDL(−) on cardiovascular risk was reinforced when LDL(−) content in LDL showed itself to have a positive association with total cholesterol (β = 0.003; P < 0.001), LDL-C (β = 0.003; p < 0.001), and non-HDL-C (β = 0.003; P < 0.001) and a negative association with HDL-C (β = −0.32; P = 0.04). Therefore, LDL(−) is an important biomarker that showed association with the lipid profile and the level of cardiovascular risk.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2

Abbreviations

BMI:

Body mass index

CAD:

Coronary artery disease

CHD:

Cardiovascular heart diseases

ELISA:

Enzyme-linked immunosorbent assay

HC:

Hypercholesterolemic

HDL-C:

High-density lipoprotein cholesterol

LDL:

Low-density lipoprotein

LDL(−):

Electronegative low-density lipoprotein

LDL-C:

Low-density lipoprotein cholesterol

PAF-AH:

Platelet-activating factor acetylhydrolase

TC:

Total cholesterol

TAG:

Triglycerides

References

  1. 1.

    World Health Organization (2006) World Health Statistics. Report. Geneva

  2. 2.

    Expert Panel on Detection, Evaluation, Treatment of High Blood Cholesterol in Adults (2001) Summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486–2497

    Article  Google Scholar 

  3. 3.

    Sociedade Brasileira de Cardiologia (2007) IV Diretriz Brasileira sobre Dislipidemias e Prevenção da Aterosclerose; Departamento de Aterosclerose da Sociedade Brasileira de Cardiologia. Arquivos Brasileiros de Cardiologia S88:2–19

    Google Scholar 

  4. 4.

    Berneis KK, Krauss RM (2002) Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res 43:1363–1379

    Article  CAS  PubMed  Google Scholar 

  5. 5.

    Toshima S, Hasegawa A, Kurabayashi M et al (2000) Circulating oxidized low density lipoprotein levels. A biochemical risk marker for coronary heart disease. Arterioscler Thromb Vasc Biol 20(10):2243–2247

    CAS  PubMed  Google Scholar 

  6. 6.

    Hulthe J, Fagerberg B (2002) Circulating oxidized LDL is associated with subclinical atherosclerosis development and inflammatory cytokines (AIR Study). Arterioscler Thromb Vasc Biol 22:1162–1167

    Article  CAS  PubMed  Google Scholar 

  7. 7.

    Oliveira JA, Sevanian A, Rodrigues RJ, Apolinário E, Abdalla DSP (2006) Minimally modified electronegative LDL and its autoantibodies in acute and chronic coronary syndromes. Clin Biochem 39:708–714

    Article  CAS  PubMed  Google Scholar 

  8. 8.

    Sánchez-Quesada JL, Benítez S, Ordóñez-Llanos J (2004) Electronegative low-density lipoprotein. Curr Opin Lipidol 15:329–335

    Article  PubMed  Google Scholar 

  9. 9.

    Chen HH, Hosken BD, Huang M, Gaubatz JW et al (2007) Electronegative LDL from familial hypercholesterolemic patients are physico-chemically heterogeneous but uniformly proapoptotic. J Lipid Res 48:177–184

    Article  CAS  PubMed  Google Scholar 

  10. 10.

    Sevanian A, Hwang J, Hodis H, Cazzolato G, Avogaro P, Bittolo-Bon G (1996) Contribution of an in vivo oxidized LDL to LDL oxidation and its association with dense LDL subpopulations. Arterioscl Thromb Vasc Biol 16:784–793

    CAS  PubMed  Google Scholar 

  11. 11.

    Sevanian A, Bittolo-Bon G, Cazzolato G et al (1997) LDL is a lipid hydroperoxide-enriched circulating lipoprotein. J Lipid Res 38:419–428

    CAS  PubMed  Google Scholar 

  12. 12.

    Chappey B, Myara I, Benoit MO, Mazière C, Mazière JC, Moatti N (1995) Characteristics of ten charge-differing subfractions isolated from human native low-density lipoproteins (LDL). No evidence of peroxidative modifications. Biochim Biophys Acta 1259(3):261–270

    PubMed  Google Scholar 

  13. 13.

    Ziouzenkova O, Asatryan L, Akmal M et al (1999) Oxidative cross-linking of ApoB100 and hemoglobin results in low density lipoprotein modification in blood. J Biol Chem 274(27):18916–18924

    Article  CAS  PubMed  Google Scholar 

  14. 14.

    Gaubatz JW, Gillard BK, Massey JB, Hoogeveen RC, Huang M, Lloyd EE, Raya JL, Yang CY, Pownall HJ (2007) Dynamics of dense electronegative low density lipoproteins and their preferential association with lipoprotein phospholipase A2. J Lipid Res 48(2):348–357

    Article  CAS  PubMed  Google Scholar 

  15. 15.

    World Health Organization (WHO) (2000) Obesity. Preventing and managing the global epidemic. Report. Geneva (WHO—Technical Report Series, 894)

  16. 16.

    IDF Clinical Guidelines Task Force (2006) Global guideline for type 2 diabetes: recommendations for standard, comprehensive, and minimal care. Diabet Med 23(6):579–593

    Article  Google Scholar 

  17. 17.

    Havel RJ, Eder HA, Bragdon JH (1955) The distribution and chemical composition of ultracentrifugally separated lipoprotein in human serum. J Clin Invest 34(9):1345–1353

    Article  CAS  PubMed  Google Scholar 

  18. 18.

    Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin-phenol reagent. J Biol Chem 193(1):265–275

    CAS  PubMed  Google Scholar 

  19. 19.

    Damasceno NRT, Sevanian A, Apolinário E, Oliveira JMA, Fernandes I, Abdalla DSP (2006) Detection of electronegative low density lipoprotein (LDL) in plasma and atherosclerotic lesions by monoclonal antibody-based immunoassays. Clin Biochem 39:28–38

    Article  CAS  PubMed  Google Scholar 

  20. 20.

    Sánchez-Quesada JL, Camacho M, Antón R, Benítez S, Vila L, Ordóñez-Llanos J (2003) Electronegative LDL of FH subjects: chemical characterization and induction of chemokine release from human endothelial cells. Atherosclerosis 166:261–270

    Article  PubMed  Google Scholar 

  21. 21.

    Araújo DB, Bertolami MC, Ferreira WP et al (2007) Simvastatin 80 mg and coadministration of simvastatin 10 mg and Ezetimibe 10 mg: effects on LDL(−) and anti-LDL(−) antibodies. Int J Atheroscler 2:272–278

    Google Scholar 

  22. 22.

    Faulin TES, Sena KCM, Telles AER, Grosso DM, Faulin EJB, Abdalla DSP (2008) Validation of a novel ELISA for measurement of electronegative low density lipoprotein. Clin Chem Lab Med 46:1769–1775

    Article  CAS  Google Scholar 

  23. 23.

    Hodis HN, Kramsch DM, Avogaro P et al (1994) Biochemical and cytotoxic characteristic of an in vivo circulating oxidized low density lipoprotein (LDL). J Lipid Res 35:669–677

    CAS  PubMed  Google Scholar 

  24. 24.

    Siqueira AF, Abdalla DS, Ferreira SR (2006) LDL: from metabolic syndrome to instability of the atherosclerotic plaque. Arq Bras Endocrinol Metabol 50(2):334–343

    PubMed  Google Scholar 

  25. 25.

    Sánchez-Quesada JL, Benítez S, Otal C, Franco M, Blanco-Vaca F, Ordóñez-Llanos J (2002) Density distribution of electronegative LDL in normolipemic and hyperlipemic subjects. J Lipid Res 43:699–705

    PubMed  Google Scholar 

  26. 26.

    Dejager S, Bruckert E, Chapman MJ (1993) Dense low density lipoprotein subspecies with diminished oxidative resistance predominate in combined hyperlipidemia. J Lipid Res 34:295–308

    CAS  PubMed  Google Scholar 

  27. 27.

    La Belle M, Blanche PJ, Krauss RM (1997) Charge properties of low density lipoprotein subclasses. J Lipid Res 38(4):690–700

    CAS  PubMed  Google Scholar 

  28. 28.

    Akanji AO, Suresh CG, Fatania HR, Al-Radwan R, Zubaid M (2007) Associations of apolipoprotein E polymorphism with low-density lipoprotein size and subfraction profiles in Arab patients with coronary heart disease. Metabolism 56(4):484–490

    Article  CAS  PubMed  Google Scholar 

  29. 29.

    Rizzo M, Pernice V, Frasheri A, Berneis K (2008) Atherogenic lipoprotein phenotype and LDL size and subclasses in patients with peripheral arterial disease. Atherosclerosis 197(1):237–241

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The present study was financially supported by grants from FAPESP (#04/11792-6). The authors acknowledge Dr Paulo Boschcov, former professor at UNIFESP, for his revision of the final version of the manuscript.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Nágila Raquel Teixeira Damasceno.

About this article

Cite this article

de Queiroz Mello, A.P., da Silva, I.T., Oliveira, A.S. et al. Electronegative Low-Density Lipoprotein is Associated with Dense Low-Density Lipoprotein in Subjects with Different Levels of Cardiovascular Risk. Lipids 45, 619–625 (2010). https://doi.org/10.1007/s11745-010-3439-7

Download citation

Keywords

  • Oxidation
  • Electronegative low-density lipoprotein
  • LDL phenotype B
  • Atherosclerosis